CNBC Top NewsCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:43:23时区推断·⟳ 抓取 19:45:05·⚡ 决策 07-23 19:54:23 +9m18s·96.1 天前
Galderma称GLP-1减重药带动医美填充需求增长
Galderma管理层称GLP-1减重人群带来面部容量流失修复需求，美学产品组合按固定汇率同比增长近25%。
📄 原文CNBC Top News↗ 原文
Ozempic face? Botox boom boosted by 'sagging face' trend, Swiss firm says
The increased use of weight-loss drugs has created a big opportunity for aesthetics company Galderma, its CEO told CNBC…
不做 Galderma（GALD.CH）
利好属于需求叙事和业绩确认，缺少未定价的离散订单或指引上修，且原文称股价反应不大；不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- CNBC报道Galderma CEO称GLP-1减重药用户增长正带动公司美学产品组合强劲增长。市场反应:原文称瑞士上市股票在上午交易中变化不大。
关键理由
- Galderma管理层称GLP-1减重人群带来面部容量流失修复需求，美学产品组合按固定汇率同比增长近25%。
- 美国市场增长32%，高于其他地区19%，与GLP-1药物渗透率提升的需求叙事一致。
主要风险
- 公司CEO同时表示机会仍处早期，且正文称瑞士上市股票盘中反应不大，短线重定价证据弱。
原文全文
展开原文 · 1,386 字
The increased use of weight-loss drugs has created a big opportunity for aesthetics company Galderma, its CEO told CNBC on Thursday.
"We were actually the first one to show that if you take two of our products [filler and Sculptra]... you can mitigate some of the facial sagging that you see if you have significant weight loss," CEO Flemming Ørnskov said.
The increasing rate of patients using the so-called GLP-1 medications like Ozempic, its weight-loss equivalent Wegovy, or Zepbound, especially in the U.S., is now feeding into "the very strong growth that we're seeing in our aesthetics portfolio," Ørnskov told CNBC's "Europe Early Edition."
"It's a significant opportunity for us, but it's still early days," he said.
About one in 10 U.S. adults now report taking GLP-1 drugs for weight loss, a rapidly expanding patient population that companies such as Galderma hope will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
Ørnskov's comments came as Galderma, which makes brands of botulinum toxin, colloquially known as botox, facial fillers and collagen stimulators, reported nearly 25% sales growth at constant currencies year-on-year.
Growth in the U.S., the by far largest market for GLP-1 drugs, outpaced growth elsewhere at 32%, versus 19% in the rest of the world.
The Swiss-listed stock was little moved in mid-morning trading.
"We were actually the first one to show that if you take two of our products [filler and Sculptra]... you can mitigate some of the facial sagging that you see if you have significant weight loss," CEO Flemming Ørnskov said.
The increasing rate of patients using the so-called GLP-1 medications like Ozempic, its weight-loss equivalent Wegovy, or Zepbound, especially in the U.S., is now feeding into "the very strong growth that we're seeing in our aesthetics portfolio," Ørnskov told CNBC's "Europe Early Edition."
"It's a significant opportunity for us, but it's still early days," he said.
About one in 10 U.S. adults now report taking GLP-1 drugs for weight loss, a rapidly expanding patient population that companies such as Galderma hope will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
Ørnskov's comments came as Galderma, which makes brands of botulinum toxin, colloquially known as botox, facial fillers and collagen stimulators, reported nearly 25% sales growth at constant currencies year-on-year.
Growth in the U.S., the by far largest market for GLP-1 drugs, outpaced growth elsewhere at 32%, versus 19% in the rest of the world.
The Swiss-listed stock was little moved in mid-morning trading.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。